Showing results (1-10 of 13) with videos related to
Sort By:
Pageof 2
Clinical Journal of Oncology Nursing|September 27, 2016
A Multidisciplinary Approach to Standardizing Processes for Blinatumomab AdministrationSamantha DePadova, Christina Howlett, Kimberly RiveraJournal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|September 18, 2014
Use of naloxone for reversal of life-threatening opioid toxicity in cancer-related painChristina Howlett, Rosa Gonzalez, Prakirthi Yerram, et al.Journal of Thrombosis and Thrombolysis|September 8, 2018
Evaluation of direct oral anticoagulants for the treatment of venous thromboembolism in the oncology populationJessica Hedvat, Christina Howlett, James McCloskey, et al.Leukemia & Lymphoma|March 16, 2013
Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse large B-cell lymphomaAnthony Mato, Tatyana Feldman, Tania Zielonka, et al.British Journal of Haematology|April 25, 2015
Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysisChristina Howlett, Sonya J Snedecor, Daniel J Landsburg, et al.American Journal of Hematology|February 19, 2015
Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemiaAnthony R Mato, Kenneth A Foon, Tatyana Feldman, et al.The Oncologist|December 21, 2018
Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective AnalysisSteven M Bair, Lauren E Strelec, Tatyana A Feldman, et al.Haematologica|February 9, 2018
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysisAnthony R Mato, Chadhi Nabhan, Meghan C Thompson, et al.Blood|September 8, 2016
Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experienceAnthony R Mato, Chadi Nabhan, Paul M Barr, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 6, 2017
Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete RemissionDaniel J Landsburg, Marissa K Falkiewicz, Joseph Maly, et al.Pageof 2